<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="http://medicalxpress.com/tmpl/default/css/default/feedRSS.xsl"?>
<rss version="2.0" 
	xmlns:media="http://search.yahoo.com/mrss/">
<channel>
<title>Medical Xpress: PHYSorg news tagged with: shareholder</title>
<link>http://medicalxpress.com/</link>
<language>en-us</language> 
<description>Medical Xpress internet news portal provides the latest news on Health and Medicine.</description>

 <item>
     <title>Roche extends its hostile takeover bid for Illumina</title>
   	 <description> Swiss pharmaceutical group Roche said Monday it is sticking by its hostile $5.7-billion (4.2 billion euros) bid for US gene mapper Illumina and is extending it for a month.</description>
	  <link>http://medicalxpress.com/news/2012-02-roche-hostile-takeover-illumina.html</link>
	 <category>Medications</category>
	 <pubDate>Mon, 27 Feb 2012 08:40:02 EST</pubDate>
	 <guid isPermaLink="false">news249553784</guid>
	 
</item>
<item>
     <title>Amgen buys Micromet for anti-leukemia drug</title>
   	 <description> Biotech giant Amgen said Thursday it was buying the German-American cancer research firm Micromet, giving it access to Micromet's promising leukemia therapy.</description>
	  <link>http://medicalxpress.com/news/2012-01-amgen-micromet-anti-leukemia-drug.html</link>
	 <category>Other</category>
	 <pubDate>Thu, 26 Jan 2012 13:57:46 EST</pubDate>
	 <guid isPermaLink="false">news246808660</guid>
	 
</item>
<item>
     <title>GlaxoSmithKline posts rising Q3 profits</title>
   	 <description> British drugmaker GlaxoSmithKline said Wednesday that third-quarter net profit rose seven percent, boosted by growth across its main pharmaceuticals, vaccines and consumer healthcare divisions.</description>
	  <link>http://medicalxpress.com/news/2011-10-glaxosmithkline-q3-profits.html</link>
	 <category>Other</category>
	 <pubDate>Wed, 26 Oct 2011 09:40:01 EST</pubDate>
	 <guid isPermaLink="false">news238840116</guid>
	 
</item>
<item>
     <title>What determines a company's performance? The shape of the CEO's face</title>
   	 <description>Believe it or not, one thing that predicts how well a CEO's company performs is the width of his face. CEOs with wider faces, like Herb Kelleher, the former CEO of Southwest Airlines, have better-performing companies than CEOs like Dick Fuld, the long-faced final CEO of Lehman Brothers. That's the conclusion of a new study which will be published in an upcoming issue of Psychological Science, a journal of the Association for Psychological Science.</description>
	  <link>http://medicalxpress.com/news/2011-08-company-ceo.html</link>
	 <category>Psychology &amp; Psychiatry</category>
	 <pubDate>Thu, 25 Aug 2011 15:08:24 EST</pubDate>
	 <guid isPermaLink="false">news233503679</guid>
	 
</item>


</channel>
</rss>
